Join MDA's 75th Anniversary: Advocate, Support, and Transform Lives

Last Crawled: Aug 21, 2025, related pages

Our AI has analyzed this business. Use the controls to generate a modernized demo or interact with the data below.

AI Redesign mda75.org/

Need a custom implementation? Contact Support

AI Analysis & Content

Meta Description

MDA celebrates 75 years of advocacy, research, and community support for muscular dystrophy, ALS, and related neuromuscular diseases.

Media Assets

Protected

No public media assets found.

h1s	75 YEARS OF Legacy. Impact. Momentum.
h2s	1949 1950 1952 1952 1952 1952 1953 1953 1955 1955 1956 1966 1971 1983 1986 1986 1988 1990 1992 1993 1995 1996 1998 1999 2000 2001 2001 2003 2006 2006 2007 2010 2011 2015 2015 2015 2016 2016 2017 2017 2017 2018 2018 2018 2018/2019 2019 2019 2019 2020 2020 2020 2020 2020 2021 2021 2021 2021 2021 2021 2022 2022 2022 2022 2022 2022 2023 2023 2023 2023 2023 2023 2023 2023 2023 2024 2024 2024 2024 2024 2024 1949 1950 1952 1952 1952 1952 1953 1953 1955 1955 1956 1966 1971 1983 1986 1986 1988 1990 1992 1993 1995 1996 1998 1999 2000 2001 2001 2003 2006 2006 2007 2010 2011 2015 2015 2015 2016 2017 2018 2018 2018 2018/2019 2019 2019 2019 2020 2020 2020 2020 2021 2021 2021 2022 2022 2022 2022 2022 2023 2023 2023 2023 2024 2024 2024 2024 2024 Join the Movement
h3s	The legacy of a community committed Dr. Ade Milhorat is one of few doctors researching muscular dystrophies worldwide The Muscular Dystrophy Association of America is founded Dean Martin, Jerry Lewis promote MDA on national radio MDA Ambassador Program launched Five MDA Local Telethons Held in Two Years The International Association Resolves to Fight Muscular Dystrophy and "Fills the Boot" The first MDA Care Centers are established National Association of Letter Carriers becomes MDA's first national sponsor Eleanor Gehrig named MDA's National Campaign Chairperson MDA holds first MDA Summer Camp Martin and Lewis Local Telethon for MDA at Carnegie Hall MDA's Legendary Labor Day Telethon Series Begins MDA Labor Day Telethon seen across the country The Orphan Drug Act (ODA) of 1983 enacted. CITGO Joins Forces with MDA MDA-funded discovery of the DMD gene launches a new era in genetic research and therapies. MDA funds SMA Cell Bank to advance gene discovery Americans with Disabilities Act (ADA) signed into law Genetic mutations causing myotonic dystrophy type 1 identified Mutations in PMP22 identified as a causative for CMT1A FDA approves Riluzole, first treatment for ALS American Medical Association honors MDA with the Lifetime Achievement Award MDA-funded work leads to three FDA-approved exon skipping drugs for Duchenne muscular dystrophy MDA funds first clinical trial for gene therapy for any type of muscular dystrophy. MDA funds research to boost SMN2 gene expression for SMA treatment. Genetic mutation causing myotonic dystrophy type 2 identified. U.S. Congress Passes the MD-CARE Act The Centers of Excellence program in muscular dystrophy research is established by NIH MDA funds the first-ever gene therapy trial for Duchenne muscular dystrophy FDA approves Lumizyme (alglucosidase alfa) for the treatment of Pompe Disease MDA funds Dr. Adrian Krainer's antisense therapy research, leading to Spinraza for SMA Surveying New Therapeutive Avenues Identification of C9ORF mutations in ALS MDA makes the difficult decision to end its historic Telethon tradition FDA approves Keveyis for treating periodic paralysis MDA establishes the MDA Resource Center to provide trusted guidance and support nationwide FDA approves Exondys 51 (eteplirsen) for the treatment of DMD FDA approves Spinraza (nusinersen) for the treatment of SMA FDA approves Emflaza (deflazacort) for the treatment of Duchenne Muscular Dystrophy FDA approves Radicava (edaravone) for the treatment of ALS FDA approves Soliris (eculizumab) for the treatment of myasthenia gravis Decoding Disease Mechanisms MDA launches the MOVR Data Hub™ Adrian Krainer, PhD, wins Breakthrough Prize for developing Spinraza, an SMA therapy FDA approves Firdapse/Ruzurgi (amifampridine) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) FDA approves Zolgensma (onasemnogenebeparvovec-xioi) for the treatment of SMA FDA approves Vyondys 53 (golodirsen) for the treatment of Duchenne muscular dystrophy MDA Hosts First Clinical and Scientific Conference FDA approves Viltepso (viltolarsen) to treat Duchenne muscular dystrophy FDA approves Evrysdi (risdiplam) to treat spinal muscular atrophy Congress passes the ALS Disability Insurance Access Act MDA launches Let's Play MDA introduces MDA Virtual Summer Camp FDA approves Vyvgart (efgartigimod alfa-fcab) to treat generalized myasthenia gravis. FDA approves Amondys 45 (casimersen) to treat Duchenne muscular dystrophy FDA approves Octagam 10% [Immune Globulin Intraveneous (Human)] to treat adult dermatomyositis FDA approves Nexviazyme (avalglucosidase alfa-ngpt) to treat late-onset Pompe disease Congress passes the ACT for ALS MDA establishes the MDA Mentorship Program FDA approves Ultomiris (ravulizumab-cwvz) to treat generalized myasthenia gravis FDA approves Relyvrio (sodium phenylbutyrate/taurursodiol) to treat ALS MDA introduces the Quest Media Lifestyle platform MDA Advocacy Collaboration Grant program launched The Centers for Medicare and Medicaid Services creates new diagnostic codes for LGMD Congress passes the FDA User Fee Reauthorization Act FDA approves Agamree (vamorolone) to treat Duchenne muscular dystrophy FDA approves Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) 65mg capsules for adults living with late-onset Pompe disease FDA approves Rystiggo (rozanolixizumab-noli) to treat generalized myasthenia gravis FDA approves Qalsody (tofersen) to treat ALS FDA approves Skyclaris (omaveloxolone) to treat Friederich's ataxia MDA Kickstart Program launched MDA creates the Gene Therapy Support Network MDA establishes MDA Connect MDA Introduces Family Getaways Program A new era of treatment for neuromuscular diseases emerges FDA approves Duvyzat (givinostat) to treat Duchenne muscular dystrophy MDA Gene Therapy Support Network honored at 2024 Advanced Therapies Awards Congress Passes Air Travel Accessibility Reforms All 50 states and DC implement newborn screening for SMA MDA College Scholarship Program Established The legacy of a community committed Dr. Ade Milhorat is one of few doctors researching muscular dystrophies worldwide The Muscular Dystrophy Association of America is founded Dean Martin, Jerry Lewis promote MDA on national radio MDA Ambassador Program launched Five MDA Local Telethons Held in Two Years The International Association Resolves to Fight Muscular Dystrophy and "Fills the Boot" The first MDA Care Centers are established National Association of Letter Carriers becomes MDA's first national sponsor Eleanor Gehrig named MDA's National Campaign Chairperson MDA holds first MDA Summer Camp Martin and Lewis Local Telethon for MDA at Carnegie Hall MDA's Legendary Labor Day Telethon Series Begins MDA Labor Day Telethon seen across the country The Orphan Drug Act (ODA) of 1983 enacted. CITGO Joins Forces with MDA MDA-funded discovery of the DMD gene launches a new era in genetic research and therapies. MDA funds SMA Cell Bank to advance gene discovery Americans with Disabilities Act (ADA) signed into law Genetic mutations causing myotonic dystrophy type 1 identified Mutations in PMP22 identified as a causative for CMT1A FDA approves Riluzole, first treatment for ALS American Medical Association honors MDA with the Lifetime Achievement Award MDA-funded work leads to three FDA-approved exon skipping drugs for Duchenne muscular dystrophy MDA funds first clinical trial for gene therapy for any type of muscular dystrophy MDA funds research to boost SMN2 gene expression for SMA treatment. Genetic mutation causing myotonic dystrophy type 2 identified. U.S. Congress Passes the MD-CARE Act The Centers of Excellence program in muscular dystrophy research is established by NIH MDA funds the first-ever gene therapy trial for Duchenne muscular dystrophy FDA approves Lumizyme (alglucosidase alfa) for the treatment of Pompe Disease MDA funds Dr. Adrian Krainer's antisense therapy research, leading to Spinraza for SMA Surveying New Therapeutive Avenues Identification of C9ORF mutations in ALS MDA makes the difficult decision to end its historic Telethon tradition FDA approves Keveyis for treating periodic paralysis MDA establishes the MDA Resource Center to provide trusted guidance and support nationwide FDA approves Exondys 51 (eteplirsen) for the treatment of DMD FDA approves Spinraza (nusinersen) for the treatment of SMA FDA approves Emflaza (deflazacort) for the treatment of Duchenne Muscular Dystrophy FDA approves Radicava (edaravone) for the treatment of ALS FDA approves Soliris (eculizumab) for the treatment of myasthenia gravis Decoding Disease Mechanisms MDA launches the MOVR Data Hub™ Adrian Krainer, PhD, wins Breakthrough Prize for developing Spinraza, an SMA therapy FDA approves Firdapse/Ruzurgi (amifampridine) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) FDA approves Zolgensma (onasemnogenebeparvovec-xioi) for the treatment of SMA FDA approves Vyondys 53 (golodirsen) for the treatment of Duchenne muscular dystrophy MDA Hosts First Clinical and Scientific Conference FDA approves Viltepso (viltolarsen) to treat Duchenne muscular dystrophy FDA approves Evrysdi (risdiplam) to treat spinal muscular atrophy Congress passes the ALS Disability Insurance Access Act MDA launches Let's Play MDA introduces MDA Virtual Summer Camp FDA approves Vyvgart (efgartigimod alfa-fcab) to treat generalized myasthenia gravis. FDA approves Amondys 45 (casimersen) to treat Duchenne muscular dystrophy FDA approves Octagam 10% [Immune Globulin Intraveneous (Human)] to treat adult dermatomyositis FDA approves Nexviazyme (avalglucosidase alfa-ngpt) to treat late-onset Pompe disease Congress passes the ACT for ALS MDA establishes the MDA Mentorship Program FDA approves Ultomiris (ravulizumab-cwvz) to treat generalized myasthenia gravis FDA approves Relyvrio (sodium phenylbutyrate/taurursodiol) to treat ALS MDA introduces the Quest Media Lifestyle platform MDA Advocacy Collaboration Grant program launched The Centers for Medicare and Medicaid Services creates new diagnostic codes for LGMD Congress passes the FDA User Fee Reauthorization Act FDA approves Agamree (vamorolone) to treat Duchenne muscular dystrophy FDA approves Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) 65mg capsules for adults living with late-onset Pompe disease FDA approves Rystiggo (rozanolixizumab-noli) to treat generalized myasthenia gravis FDA approves Qalsody (tofersen) to treat ALS FDA approves Skyclaris (omaveloxolone) to treat Friederich's ataxia MDA Kickstart Program launched MDA creates the Gene Therapy Support Network MDA establishes MDA Connect MDA Introduces Family Getaways Program A new era of treatment for neuromuscular diseases emerges FDA approves Duvyzat (givinostat) to treat Duchenne muscular dystrophy MDA Gene Therapy Support Network honored at 2024 Advanced Therapies Awards Congress Passes Air Travel Accessibility Reforms All 50 states and DC implement newborn screening for SMA MDA College Scholarship Program Established Get Involved Make a Gift Become an Advocate Sign Up for MDA News & Updates
title	Join MDA's 75th Anniversary: Advocate, Support, and Transform Lives
emails	[email protected]
robots	max-image-preview:large
keywords	MDA 75th anniversary, muscular dystrophy, advocacy, community support, ALS, gene therapy, research, donate
og_title	Join MDA's 75th Anniversary: Advocate, Support, and Transform Lives
addresses	1966 by a single station, WNEW-TV in New York 72 gene mutation as the most common genetic cause of AL and new paths for MD 1966 by a single station, WNEW-TV in New York 72 gene mutation as the most common genetic cause of AL and new paths for MD
canonical	https://mda75.org/
text_size	61412
rta_rating	None
h1_analysis	ok
h2_analysis	147 found
og_site_name	MDA 75th Anniversary
url_analysis
phone_numbers	60607 800-572-1717 2017. 2017
summary_issues	title: long
title_analysis	long
cc_2025_43_count	1
meta_description	MDA celebrates 75 years of advocacy, research, and community support for muscular dystrophy, ALS, and related neuromuscular diseases.
canonical_analysis	self-referencing
responsive_analysis	score: 15 messages_bad: [] messages_good: ['Recommended viewport tag found.', 'Potential responsive CSS (@media, max/min-width) detected in HTML source.']
searchengine_analysis	score: 30 messages_bad: [] messages_good: ['Meta description tag found.', 'H1 tag(s) found.', 'Site uses HTTPS.', 'Robots meta tag found: max-image-preview:large']
meta_description_analysis	ok

Contact Details

Email [email protected]
Phone 60607 800-572-1717,2017. 2017

Social Profiles

Ask AI Assistant

Summary SEO Report Draft Email

Ask anything about this business data...